Clinical trials are a major research tool for enhancing the medical knowledge and patient care. Obsessive-Compulsive Disorder equally affects men, women, and children of all races, ethnicities, and backgrounds. This disease can start at any time from preschool to adulthood. Research & development is essential in all the industries which includes industries dealing in obsessive compulsive disorder drugs. According to the FDA, generic drugs can cost an expected 85 percent less than the medicines they are designed to copy.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-obsessive-compulsive-disorder-ocd-drug-market
Data Bridge Market Research analyses that the Obsessive-Compulsive Disorder (OCD) Drugs Market is expected to reach USD 996.90 million by 2028 from USD 505.04 million in 2020, growing at a substantial CAGR of 9.7% in the forecast period of 2021 to 2028. The increasing demand for the obsessive-compulsive disorder (OCD) drugs will provide potential opportunities for the market growth in the forecast period.
Increasing number of obsessive-compulsive disorder (OCD) is anticipated to drive the market's growth rate
OCD can occur at any age, but there are usually two age ranges when OCD tends to first appears, between the ages 8 and 12 years and between the late teen years and early adulthood. New cases are less common after age 40 years. OCD ranks among the 10 top causes of disability globally. OCD affects a large number of children. While there is no specific cure for OCD, there are effective treatments available through exposure and response prevention and medication management.
For instance,
As per the records of International OCD Foundation estimates, there are around 1 in 100 adults or between 2 to 3 million adults in the U.S. currently have OCD and there are at least 1 in 200 or 500,000 kids and teens that have OCD.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Severity (Mild to Moderate, Moderate to Severe),Sub-Type (Contamination Obsessions with Washing/Cleaning Compulsion, Harm Obsessions With Checking Compulsions, Obsessions Without Visible Compulsions, Symmetry Obsessions with ordering, arranging and counting compulsions, hoarding, others),Drugs (Antidepressants, Antipsychotics, NMDA Blocker, Others), Route of Administration (Oral, Parenteral), Population type (Pediatrics, Adults), By End User (Hospitals, specialty Clinics, Home healthcare, others), By Distribution Channel (Hospital pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Lilly (U.S.), Viatria Inc. (U.S.), H. LUNDBECK A/S (Denmark), GSK plc. (U.K.), Pfizer Inc. (U.S.), Sebela Pharmaceuticals (U.S.), Zydus Group (U.S.), Lupin (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceutical industries Ltd. (Israel), Wockhardt (India), Alvogen (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (U.S.), Apotex Inc. (India), and Lannett (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global obsessive-compulsive disorder drug market is categorized into seven notable segments which are based on severity, subtype, drugs, route of administration, population type, end-user, and distribution channel.
- On the basis of severity, the global obsessive-compulsive disorder (OCD) drug market is segmented into mild to moderate and moderate to severe.
The moderate to severe segment of severity type is anticipated to dominate the obsessive-compulsive disorder (OCD) drugs market
The moderate to severe segment is expected to dominate the market with 26.72% market share due to a rise in the cases of incidence rate of infectious diseases among the population globally are predicted to dominate the market.
- On the basis of subtype, the global obsessive-compulsive disorder (OCD) drug market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging and counting compulsions, hoarding and others.
The contamination obsessions with washing/cleaning compulsion segment of subtype is anticipated to dominate the obsessive-compulsive disorder (OCD) drugs market
The contamination obsessions with washing/cleaning compulsion segment is expected to dominate the market with 67.99% market share due to developments in the treatment, therapies, and introduction of novel treatments are expected to dominate the market.
- On the basis of drugs, the global obsessive-compulsive disorder (OCD) drug market is segmented into antidepressants, antipsychotics, NMDA blocker and others.The antidepressants segment is expected to dominate the global obsessive-compulsive disorder drug market with 58.65% market share due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the development of latest treatment are expected to dominate the market.
- On the basis of route of administration, the obsessive-compulsive disorder (OCD) drug market is segmented into oral and parenteral. The oral segment is expected to dominate the market with 89.80% market share because of novel treatment and advancements in therapies are expected to dominate the market.
- On the basis of population type, the obsessive-compulsive disorder (OCD) drug market is segmented into pediatrics and adults. The adults segment is expected to dominate the market with 74.00% market share due to research and development to improve pharmacology, bioavailability, safety, and dosage parameters are anticipated to dominate the market.
- On the basis of end user, the obsessive-compulsive disorder (OCD) drug market is segmented into hospitals, specialty clinics, home healthcare and others. The hospitals segment is expected to dominate the market with 45.35% market share because of an increase in the cases of incidence rate of infectious diseases among the population globally is predicted to dominate the market.
- On the basis of distribution channel, the obsessive-compulsive disorder (OCD) drug market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. The hospital pharmacy segment is expected to dominate the market with 59.69% market share due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are expected to dominate the market.
Major Players
Data Bridge Market Research recognizes the following companies as the major obsessive-compulsive disorder (OCD) drugs market players in obsessive-compulsive disorder (OCD) drugs market are Abbott (U.S.), Lilly (U.S.), Viatria Inc. (U.S.), H. LUNDBECK A/S (Denmark), GSK plc. (U.K.), Pfizer Inc. (U.S.), Sebela Pharmaceuticals (U.S.), Zydus Group (U.S.), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceutical industries Ltd. (Israel), Wockhardt (India), Alvogen (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (U.S.), Apotex Inc. (India), and Lannett (U.S.)
Market Development
- In 2021, Apotex Inc. announced the initiation of voluntary Type I recall of APO-AMITRIPTYLINE 10 mg.
- In 2020, US-based Jubilant Cadista Pharmaceuticals declared the initiation of voluntary class II recall of 50 mg clomipramine Hydrochloride capsules in 30-count bottles.
- In 2021, Amneal Pharmaceuticals Inc. and Kashiv Biosciences LLC announced that Amneal Pharmaceuticals had completed its previously announced acquisition of a 98% interest in Kashiv Speciality Pharmaceuticals LLC
- In 2020, Par Pharmaceuticals announced the completion of the acquisition between Endo International Plc. And Biospecifics Technologies Corp. for USD 88.50 per share in an all-cash transaction
Regional Analysis
Geographically, the countries covered in the obsessive-compulsive disorder (OCD) drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in obsessive-compulsive disorder (OCD) drugs market during the forecast period 2021 to 2028
North America dominates the obsessive-compulsive disorder (OCD) drugs market because of the treatment options and improving healthcare infrastructure in U.S. North America will continue to dominate the obsessive compulsive disorder (OCD) drugs market in terms of market share and will continue to flourish its dominance during the forecast period. This is because of the rise in cases of OCD, and surge in elderly population.
Asia-Pacific is estimated to be the fastest growing region in obsessive-compulsive disorder (OCD) drugs market the forecast period 2021 to 2028
Asia-Pacific is expected to grow during the forecast period of 2021 to 2028 because of the increase in investment in innovative R&D for novel drug products. Additionally, several advancements in the anti-anxiety in the region.
For more detailed information about obsessive-compulsive disorder (OCD) drugs market report, click here – https://www.databridgemarketresearch.com/reports/global-obsessive-compulsive-disorder-ocd-drug-market
